Genesis Financial Group LLC Acquires Shares of 48,805 Medtronic PLC $MDT

Genesis Financial Group LLC acquired a new stake in Medtronic PLC (NYSE:MDT) in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 48,805 shares of the medical technology company’s stock, valued at approximately $4,688,000. Medtronic makes up 2.7% of Genesis Financial Group LLC’s holdings, making the stock its 10th biggest holding.

Other large investors have also made changes to their positions in the company. Corundum Trust Company INC purchased a new stake in Medtronic in the 3rd quarter worth $27,000. Lodestone Wealth Management LLC purchased a new position in Medtronic during the fourth quarter valued at $27,000. Board of the Pension Protection Fund purchased a new position in Medtronic during the fourth quarter valued at $29,000. GoalVest Advisory LLC acquired a new stake in shares of Medtronic in the fourth quarter valued at about $29,000. Finally, Valley Wealth Managers Inc. acquired a new stake in shares of Medtronic in the third quarter valued at about $29,000. 82.06% of the stock is owned by institutional investors and hedge funds.

Medtronic Stock Up 0.6%

MDT stock opened at $86.61 on Friday. The company has a current ratio of 2.54, a quick ratio of 1.87 and a debt-to-equity ratio of 0.57. The firm has a 50-day moving average of $94.76 and a two-hundred day moving average of $96.27. Medtronic PLC has a 12 month low of $79.55 and a 12 month high of $106.33. The company has a market cap of $111.19 billion, a price-to-earnings ratio of 24.12, a PEG ratio of 2.22 and a beta of 0.75.

Medtronic (NYSE:MDT) last issued its earnings results on Tuesday, February 17th. The medical technology company reported $1.36 earnings per share for the quarter, topping the consensus estimate of $1.34 by $0.02. Medtronic had a return on equity of 14.82% and a net margin of 13.00%.The business had revenue of $9.02 billion for the quarter, compared to analysts’ expectations of $8.89 billion. During the same period in the previous year, the firm posted $1.38 EPS. The business’s revenue for the quarter was up 5.8% compared to the same quarter last year. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. As a group, analysts forecast that Medtronic PLC will post 5.46 earnings per share for the current fiscal year.

Medtronic Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, April 17th. Stockholders of record on Friday, March 27th will be issued a dividend of $0.71 per share. This represents a $2.84 annualized dividend and a dividend yield of 3.3%. The ex-dividend date is Friday, March 27th. Medtronic’s payout ratio is currently 79.11%.

Analyst Ratings Changes

Several research firms recently weighed in on MDT. Weiss Ratings restated a “buy (b-)” rating on shares of Medtronic in a research report on Monday, December 29th. Leerink Partners reiterated an “outperform” rating and issued a $119.00 price objective on shares of Medtronic in a report on Tuesday, March 10th. UBS Group reissued a “neutral” rating and set a $104.00 target price on shares of Medtronic in a report on Wednesday, February 4th. Daiwa Securities Group decreased their target price on Medtronic from $117.00 to $115.00 and set a “buy” rating on the stock in a research report on Friday, February 27th. Finally, Piper Sandler lowered their price target on Medtronic from $105.00 to $91.00 and set a “neutral” rating on the stock in a research note on Wednesday. One analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating and ten have issued a Hold rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $109.85.

Insider Buying and Selling at Medtronic

In other news, EVP Harry Skip Kiil sold 52,524 shares of the business’s stock in a transaction dated Thursday, February 19th. The shares were sold at an average price of $97.71, for a total transaction of $5,132,120.04. Following the transaction, the executive vice president owned 32,768 shares of the company’s stock, valued at approximately $3,201,761.28. The trade was a 61.58% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 0.26% of the company’s stock.

Medtronic Company Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).